Key result
Simvastatin restored the cardioprotective effects of ischemic preconditioning on myocardial infarct size during hyperglycemia through nitric oxide-mediated signaling.
Why the study?
Does simvastatin restore the cardioprotective effects of ischemic preconditioning during hyperglycemia in a canine model of coronary occlusion and reperfusion?
Does simvastatin restore the cardioprotective effects of ischemic preconditioning during hyperglycemia in a canine model of coronary occlusion and reperfusion?
Simvastatin restores the cardioprotective effects of ischemic preconditioning during hyperglycemia via a nitric oxide-mediated mechanism in a canine model.
Answers are grounded in this paper and cite their sources.
Should not alter clinical management; hypothesis-generating for statin augmentation of preconditioning in metabolic stress.
BACKGROUND: A growing body of evidence indicates that statins decrease perioperative cardiovascular risk and that these drugs may be particularly efficacious in diabetes. Diabetes and hyperglycemia abolish the cardioprotective effects of ischemic preconditioning (IPC). The authors tested the hypothesis that simvastatin restores the beneficial effects of IPC during hyperglycemia through a nitric oxide-mediated mechanism. METHODS: Myocardial infarct size was measured in dogs (n = 76) subjected to coronary artery occlusion and reperfusion in the presence or absence of hyperglycemia (300 mg/dl) with or without IPC in separate groups. Additional dogs received simvastatin (20 mg orally daily for 3 days) in the presence or absence of IPC and hyperglycemia. Other dogs were pretreated with N-nitro-l-arginine methyl ester (30 mg intracoronary) with or without IPC, hyperglycemia, and simvastatin. RESULTS: Ischemic preconditioning significantly (P < 0.05) reduced infarct size (n = 7, 7 +/- 2%) as compared with control (n = 7, 29 +/- 3%). Hyperglycemia (n = 7), simvastatin (n = 7), N-nitro-l-arginine methyl ester alone (n = 7), and simvastatin with hyperglycemia (n = 6) did not alter infarct size. Hyperglycemia (n = 7, 24 +/- 2%), but not N-nitro-l-arginine methyl ester (n = 5, 10 +/- 1%), blocked the protective effects of IPC. Simvastatin restored the protective effects of IPC in the presence of hyperglycemia (n = 7, 14 +/- 1%), and this beneficial action was blocked by N-nitro-l-arginine methyl ester (n = 7, 29 +/- 4%). CONCLUSIONS: The results indicate that simvastatin restored the cardioprotective effects of IPC during hyperglycemia by nitric oxide-mediated signaling. The results also suggest that enhanced cardioprotective signaling could be a mechanism for statin-induced decreases in perioperative cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2008) studied Myocardial infarction during hyperglycemia (n=76). Simvastatin vs. Hyperglycemia without simvastatin was evaluated on Myocardial infarct size. Simvastatin restored the cardioprotective effects of ischemic preconditioning on myocardial infarct size during hyperglycemia through nitric oxide-mediated signaling.
Synapse has enriched 10 related papers. Consider them for comparative context: